Latest News on LRMR

Financial News Based On Company


Advertisement
Advertisement

Leerink reiterates Larimar Therapeutics stock rating at Outperform By Investing.com

https://in.investing.com/news/stock-market-news/leerink-reiterates-larimar-therapeutics-stock-rating-at-outperform-93CH-5712729
Leerink maintained its Outperform rating and $13.00 price target for Larimar Therapeutics (NASDAQ:LRMR) after the company submitted its biologics license application for nomlabofusp in Friedreich's ataxia. Larimar is preparing for a potential U.S. launch in Q3 2027 and ended the third quarter with approximately $129 million in cash. While Leerink maintained its 2026 EPS estimate, it lowered the 2027 EPS to negative $0.85 due to higher spending assumptions.

Form 4 Larimar Therapeutics Inc: Jeffrey W. Sherman (Director) For: 16 November

https://ca.investing.com/news/stock-market-news/form-4-larimar-therapeutics-inc-jeffrey-w-sherman-director-for-16-november-93CH-4962785
Jeffrey W. Sherman, a Director at Larimar Therapeutics Inc (LRMR), filed a Form 4 for transactions related to the company on November 16. This filing, published by Investing.com, details insider trading activities.

Form 4 Larimar Therapeutics Inc: Jeffrey W. Sherman (Director) For: 16 November

https://ng.investing.com/news/stock-market-news/form-4-larimar-therapeutics-inc-jeffrey-w-sherman-director-for-16-november-93CH-2811907
Jeffrey W. Sherman, a director at Larimar Therapeutics Inc. (LRMR), filed a Form 4 for transactions related to November 16. The article simply reports this SEC filing without providing specific details of the transaction. Larimar Therapeutics Inc. (LRMR) saw a 7.36% increase in its stock price as mentioned in the article.

Larimar Therapeutics (LRMR) director Sherman bought 3,289.47 shares for $10.1K at $3.06

https://www.quantisnow.com/insight/director-sherman-jeffrey-w-bought-10058-worth-of-shares-3289-6794939
Larimar Therapeutics (LRMR) director Jeffrey W. Sherman purchased 3,289.47 shares of the company's common stock for approximately $10,100 at a price of $3.06 per share on November 16, 2026. This transaction increased his direct holdings to 8,289.47 shares. The article also provides historical context on LRMR's stock performance following previous headlines and details other recent insider transactions.

Larimar Therapeutics Releases Q3 2026 Financial Results

https://news.alphastreet.com/larimar-therapeutics-releases-q3-2026-financial-results/amp/
Larimar Therapeutics (NASDAQ: LRMR) reported a net loss of $31.1 million for Q3 2026, with a basic and diluted net loss per share of $0.29. This represents a significant 52.5% improvement from the $0.61 per share loss in Q3 2025. Wall Street analysts maintain a positive outlook, with a consensus of 8 buy, 1 hold, and 0 sell ratings for the clinical-stage biotechnology company.
Advertisement

Larimar Therapeutics Releases Q3 2026 Financial Results

https://news.alphastreet.com/larimar-therapeutics-releases-q3-2026-financial-results/
Larimar Therapeutics (NASDAQ: LRMR) reported a net loss of $31.1 million, or $0.29 per share, for Q3 2026, marking a significant 52.5% improvement from the previous year. The clinical-stage biotechnology company continues to develop its cell-penetrating peptide technology for rare disease treatments. Wall Street analysts maintain a positive outlook, with 8 buy ratings and 1 hold rating, reflecting optimism about the company's technology platform.

Form 4 Larimar Therapeutics Inc: Joseph Truitt (Director) For: 11 November

https://ca.investing.com/news/stock-market-news/form-4-larimar-therapeutics-inc-joseph-truitt-director-for-11-november-93CH-4960962
This article reports on a Form 4 filing for Larimar Therapeutics Inc, indicating a transaction by Director Joseph Truitt on November 11th. The filing provides details on insider trading activity for the company. The article originates from Investing.com, a financial markets news source.

Larimar Therapeutics, Inc. (LRMR) Tops Q3 EPS by 6c

https://www.streetinsider.com/Earnings/Larimar+Therapeutics%2C+Inc.+%28LRMR%29+Tops+Q3+EPS+by+6c/27348342.html
Larimar Therapeutics, Inc. (NASDAQ: LRMR) announced its Q3 EPS of ($0.29), outperforming analyst estimates of ($0.35) by $0.06. This report highlights the company's financial performance relative to market expectations.

Larimar Therapeutics CEO Carole Ben-Maimon buys $49,953 in stock. By Investing.com

https://ca.investing.com/news/stock-market-news/larimar-therapeutics-ceo-carole-benmaimon-buys-49953-in-stock-93CH-4960503
Larimar Therapeutics CEO Carole Ben-Maimon purchased 18,050 restricted stock units (RSUs) worth $49,953 on November 11, 2026, increasing her direct holdings to 386,326 shares. This transaction occurred amidst a 19% weekly stock gain, with InvestingPro analysis indicating the stock is undervalued. The company recently appointed John B. Harlow, Jr. as President and COO, and Wedbush reiterated an Outperform rating with an $11.00 price target for its nomlabofusp therapy.

Larimar Therapeutics Reports Third Quarter 2026 Financial and Business Update

https://www.globenewswire.com/news-release/2026/11/16/3403379/0/en/larimar-therapeutics-reports-third-quarter-2026-financial-and-business-update.html
Larimar Therapeutics has reported its third quarter 2026 financial and business results, highlighting the completion of its BLA submission for nomlabofusp to treat Friedreich’s ataxia, seeking accelerated approval. The company is preparing for a potential U.S. launch in Q3 2027 and reported $128.7 million in cash, cash equivalents, and marketable securities, projecting a cash runway into late Q2 2027. Net loss for Q3 2026 was $31.1 million, a decrease from $47.7 million in Q3 2025, primarily due to reduced drug manufacturing activities.
Advertisement

Larimar Therapeutics Inc. (NASDAQ: LRMR) Shares Gain 12% After Completing Nomlabofusp Regulatory Submission

https://kalkine.com.au/news/healthcare/larimar-therapeutics-inc-nasdaq-lrmr-shares-gain-12-after-completing-nomlabofusp-regulatory-submission
Larimar Therapeutics Inc. (NASDAQ: LRMR) shares surged 11.85% after completing its rolling Biologics License Application (BLA) for nomlabofusp, an investigational protein replacement therapy for Friedreich’s ataxia. The submission seeks accelerated US approval, leveraging prior FDA alignment on components like skin frataxin as a potential surrogate endpoint. The company is also continuing enrollment for its global confirmatory Phase 3 FORWARD-FA trial.

Larimar Therapeutics chief development officer buys $13,549 in stock

https://www.investing.com/news/insider-trading-news/larimar-therapeutics-chief-development-officer-buys-13549-in-stock-93CH-5024035
Gopi Shankar, Chief Development Officer at Larimar Therapeutics, Inc. (NASDAQ:LRMR), purchased 5,000 shares of the company's common stock for $13,549 on November 11, 2026. This insider transaction follows a nearly 13% stock return over the last week and the appointment of John B. Harlow, Jr. as president and COO. Wedbush also reiterated an Outperform rating with an $11.00 price target, citing potential approval for Larimar's nomlabofusp.

Larimar Therapeutics (LRMR) CEO buys shares, bringing reported direct holdings to 386,326.

https://www.stocktitan.net/sec-filings/LRMR/form-4-larimar-therapeutics-inc-insider-trading-activity-7da6403c420b.html
Larimar Therapeutics, Inc. (LRMR) President and CEO Carole Ben-Maimon purchased 18,050 shares on November 11, 2026, at a weighted-average price of $2.7675 per share, increasing her direct holdings to 386,326 shares. The purchases were executed in multiple transactions ranging from $2.765 to $2.77. This insider activity, reported via a Form 4 SEC filing, is deemed to have a "Positive" filing sentiment and a "High" filing impact.

Larimar Therapeutics director purchases $21,800 in shares

https://www.investing.com/news/insider-trading-news/larimar-therapeutics-director-purchases-21800-in-shares-93CH-5023721
A director at Larimar Therapeutics, Frank E. Thomas, recently purchased 8,000 shares of company stock for $21,800. This insider transaction follows a 16% gain in the stock over the past week, with analysis suggesting the stock is undervalued. The company also recently appointed John B. Harlow, Jr. as president and COO, and Wedbush reiterated an Outperform rating with an $11 price target.

Larimar Therapeutics CFO Celano purchases $49,991 in stock

https://www.investing.com/news/insider-trading-news/larimar-therapeutics-cfo-celano-purchases-49991-in-stock-93CH-5024045
Michael Celano, CFO of Larimar Therapeutics (NASDAQ:LRMR), recently purchased 18,460 shares of company stock totaling $49,991. These transactions occurred on November 11, 2026, with prices ranging from $2.695 to $2.715 per share. The purchase follows a 13% stock gain over the past week, and InvestingPro analysis suggests the stock is currently undervalued despite profitability challenges common in clinical-stage biotechs.
Advertisement

Form 4 Larimar Therapeutics Inc: Gopi Shankar (Chief Development Officer) For: 11 November

https://uk.investing.com/news/stock-market-news/form-4-larimar-therapeutics-inc-gopi-shankar-chief-development-officer-for-11-november-93CH-4979576
This article reports on a Form 4 filing from Larimar Therapeutics Inc, specifically detailing a transaction related to Gopi Shankar, the Chief Development Officer, on November 11. Form 4 filings are regulatory documents that disclose changes in the beneficial ownership of a company's securities by insiders. The article indicates that Larimar Therapeutics Inc (LRMR) experienced a -1.10% change.

Form 4 Larimar Therapeutics Inc: Carole Ben-Maimon (Director, President and CEO) For: 11 November

https://ng.investing.com/news/stock-market-news/form-4-larimar-therapeutics-inc-carole-benmaimon-director-president-and-ceo-for-11-november-93CH-2804870
This article reports on a Form 4 filing for Larimar Therapeutics Inc, detailing an insider transaction involving Carole Ben-Maimon, who serves as Director, President, and CEO. The filing is specifically for November 11. The article highlights the company's stock symbol LRMR.

Larimar Therapeutics (LRMR) director Thomas bought 8,000 shares for $21.8K at $2.73

https://www.quantisnow.com/insight/director-thomas-frank-e-bought-21800-worth-of-shares-8000-6788971
Frank E. Thomas, a director at Larimar Therapeutics (LRMR), purchased 8,000 shares of the company's common stock for $21.8K at a price of $2.73 per share on November 11, 2026. This transaction increased his direct holdings by 114% to a total of 15,000 shares. The purchase was reported via an SEC Form 4 filing, indicating an open-market acquisition.

Larimar Therapeutics (LRMR) CFO Celano bought 18,460 shares for $50K at $2.71

https://www.quantisnow.com/insight/chief-financial-officer-celano-michael-bought-49992-worth-of-shares-6788947
Larimar Therapeutics (LRMR) CFO Michael Celano purchased 18,460 shares of the company's common stock for approximately $50,000 at a weighted average price of $2.71 per share. This transaction increased his direct holdings by 9% to 234,245 shares. The purchase was reported via an SEC Form 4 filing on November 11, 2026, indicating an open-market acquisition.

Chief development officer buys Larimar Therapeutics (LRMR) shares at $2.7098 each.

https://www.stocktitan.net/sec-filings/LRMR/form-4-larimar-therapeutics-inc-insider-trading-activity-e9295edfb1e7.html
Gopi Shankar, the Chief Development Officer of Larimar Therapeutics, purchased 5,000 common shares of the company (LRMR) on November 11, 2026, at a price of $2.7098 per share. This transaction increased his direct ownership to 81,443 shares. The purchase was reported via a Form 4 SEC filing, indicating a positive sentiment and moderate impact.
Advertisement

Form 4 Larimar Therapeutics Inc: Thomas Edward Hamilton (Director) For: 12 November

https://ca.investing.com/news/stock-market-news/form-4-larimar-therapeutics-inc-thomas-edward-hamilton-director-for-12-november-93CH-4955283
This article reports on a Form 4 filing for Larimar Therapeutics Inc, indicating a transaction by Director Thomas Edward Hamilton on November 12. The Form 4 is a document that must be filed with the U.S. Securities and Exchange Commission (SEC) whenever there is a change in the ownership of company stock by company insiders. The article provides the basic announcement without further details on the nature of the transaction.

Larimar Therapeutics, Inc. Stock 12‑Month Price Target Cut to $13.62, Implies 399% Upside

https://www.tradingview.com/news/tradingview:feb7c509e4365:0-larimar-therapeutics-inc-stock-12-month-price-target-cut-to-13-62-implies-399-upside/
Analysts have revised Larimar Therapeutics, Inc.'s average 12-month price target down to $13.62 from $14.4, with individual forecasts ranging from $5 to $25 per share. Despite the cut, this new target still suggests a substantial 399% potential upside based on the stock's closing price on November 11. The consensus rating among 9 covering analysts remains a "Buy."

Larimar Therapeutics (LRMR) Stock Price, Chart & Analysis

https://www.debelegger.nl/en/stock/LRMR.US
This article provides a detailed analysis of Larimar Therapeutics (LRMR) stock, including its latest price, market capitalization, and key financial figures. It covers aspects like revenue growth, net margin, debt, and dividend policy. The report also highlights analyst price targets and a comparison of LRMR's performance within its 52-week range.

Wedbush reiterates Larimar Therapeutics stock rating at Outperform

https://www.investing.com/news/analyst-ratings/wedbush-reiterates-larimar-therapeutics-stock-rating-at-outperform-93CH-5014689
Wedbush has reiterated an Outperform rating for Larimar Therapeutics (NASDAQ:LRMR) with an $11.00 price target, citing the potential for nomlabofusp to gain approval for Friedreich’s ataxia. Despite the positive outlook on the drug's potential, the firm acknowledges a financing overhang and the company's "WEAK" financial health, with shares currently trading near a 52-week low. The firm indicates that a Complete Response Letter could lead to a $0 valuation, while approval could see shares reach the $11 target.

Wedbush reiterates Larimar Therapeutics stock rating at Outperform By Investing.com

https://ca.investing.com/news/stock-market-news/wedbush-reiterates-larimar-therapeutics-stock-rating-at-outperform-93CH-4945816
Wedbush has reiterated an Outperform rating for Larimar Therapeutics (NASDAQ:LRMR) with an $11.00 price target, citing the potential approval of nomlabofusp for Friedreich’s ataxia. Despite a "WEAK" financial health rating and a potential financing overhang, the firm sees significant upside if the drug gains approval and receives a Priority Review Voucher. The stock currently trades around $2.50, closer to its 52-week low, while analyst targets range broadly from $5 to $26.
Advertisement

Larimar Completes BLA Submission for Nomlabofusp in Friedreich’s Ataxia

https://www.quiverquant.com/news/Larimar+Completes+BLA+Submission+for+Nomlabofusp+in+Friedreich%E2%80%99s+Ataxia
Larimar Therapeutics (LRMR) has completed its Biologics License Application (BLA) submission to the FDA for accelerated approval of nomlabofusp for Friedreich’s ataxia, supported by data showing sustained increases in skin frataxin. The company expects a BLA submission acceptance decision in early 2027 and aims for a U.S. launch in Q3 2027 if approved. Additionally, the article details recent insider trading activity and institutional investor movements in LRMR stock.

Form 8K Larimar Therapeutics Inc For: 9 November By Investing.com

https://uk.investing.com/news/stock-market-news/form-8k-larimar-therapeutics-inc-for-9-november-93CH-4969470
Larimar Therapeutics Inc. filed a Form 8K on November 9, 2026, as reported by Investing.com. The article briefly mentions the filing and includes the stock symbol LRMR, which showed a 5.86% increase. The content largely consists of market data and news headlines, with minimal specific detail about the Form 8K filing itself.

Larimar Therapeutics Completes Rolling BLA Submission Seeking Accelerated Approval of Nomlabofusp for Friedreich’s Ataxia

https://www.stocktitan.net/news/LRMR/larimar-therapeutics-completes-rolling-bla-submission-seeking-j8te16dxsrye.html
Larimar Therapeutics (LRMR) has completed its rolling Biologics License Application (BLA) submission to the FDA for accelerated approval of nomlabofusp to treat Friedreich’s ataxia. The application leverages increased skin frataxin levels as a potential surrogate endpoint, a measure the FDA is willing to consider, and is supported by data from an ongoing open-label study showing sustained frataxin increases and directional clinical improvements. Larimar anticipates submission acceptance in early 2027, potential U.S. approval by mid-2027, and a Q3 2027 launch if approved, notably providing a potential therapy for children under 16 who currently lack approved treatments.

Larimar Therapeutics Completes Rolling BLA Submission

https://www.globenewswire.com/news-release/2026/11/09/3398967/0/en/larimar-therapeutics-completes-rolling-bla-submission-seeking-accelerated-approval-of-nomlabofusp-for-friedreich-s-ataxia.html
Larimar Therapeutics has completed its rolling Biologics License Application (BLA) submission to the FDA for nomlabofusp, seeking accelerated approval for the treatment of Friedreich’s ataxia (FA). The submission is supported by data showing sustained increases in skin frataxin, a potential novel surrogate endpoint, and directional clinical improvements in patients. Larimar is also enrolling patients in its global confirmatory Phase 3 study, FORWARD-FA, and aims for a potential U.S. launch in Q3 2027 if approved.

Form 8K Larimar Therapeutics Inc For: 9 November By Investing.com

https://ca.investing.com/news/stock-market-news/form-8k-larimar-therapeutics-inc-for-9-november-93CH-4944260
This article from Investing.com announces that Larimar Therapeutics Inc. filed a Form 8K on November 9, 2026. The filing is a routine disclosure required by the SEC for significant events. The brief piece includes a stock ticker for Larimar Therapeutics (LRMR) and notes a minor increase in its value.
Advertisement

Larimar Therapeutics Announces Three Poster Presentations for the Nomlabofusp Program at the Upcoming International Congress for Ataxia Research

https://www.manilatimes.net/2026/11/06/tmt-newswire/globenewswire/larimar-therapeutics-announces-three-poster-presentations-for-the-nomlabofusp-program-at-the-upcoming-international-congress-for-ataxia-research/2463498
Larimar Therapeutics, Inc. announced three poster presentations for its nomlabofusp program at the International Congress for Ataxia Research (ICAR) 2026. These presentations will include interim clinical data from an ongoing open-label study, as well as new plasma lipid and gene expression analyses in Friedreich’s ataxia patients treated with nomlabofusp. The presentations are scheduled for November 12, 2026, at the Cobb Convention Center in Atlanta, Georgia.

Larimar Therapeutics Announces Three Poster Presentations

https://www.globenewswire.com/news-release/2026/11/05/3397038/0/en/larimar-therapeutics-announces-three-poster-presentations-for-the-nomlabofusp-program-at-the-upcoming-international-congress-for-ataxia-research.html
Larimar Therapeutics announced three poster presentations for its nomlabofusp program at the International Congress for Ataxia Research (ICAR) 2026. These presentations will include interim clinical data from an ongoing open-label study, as well as new analyses on plasma lipid profiles and gene expression in Friedreich's ataxia patients treated with nomlabofusp. The presentations are scheduled for Thursday, November 12, 2026, during the Poster Session Day 3 at the Cobb Convention Center.

Larimar Therapeutics Announces Three Poster Presentations

https://www.globenewswire.com/fr/news-release/2026/11/05/3397038/0/en/larimar-therapeutics-announces-three-poster-presentations-for-the-nomlabofusp-program-at-the-upcoming-international-congress-for-ataxia-research.html
Larimar Therapeutics, Inc. announced three poster presentations for its nomlabofusp program at the International Congress for Ataxia Research (ICAR) 2026. These presentations will include interim clinical data from an ongoing open-label study, as well as new plasma lipid and gene expression analyses in Friedreich’s ataxia patients treated with nomlabofusp. The presentations are scheduled for November 12, 2026, during the poster session at the Cobb Convention Center.

Larimar Therapeutics Announces Three Poster Presentations for the Nomlabofusp Program at the Upcoming International Congress for Ataxia Research

https://finance.yahoo.com/healthcare/articles/larimar-therapeutics-announces-three-poster-210500551.html
Larimar Therapeutics will present three posters on its nomlabofusp program at the International Congress for Ataxia Research (ICAR) 2026. The presentations will include interim clinical data from an open-label study, as well as new plasma lipid and gene expression analyses in Friedreich's ataxia patients treated with nomlabofusp. These presentations are scheduled for November 12, 2026, in Atlanta, Georgia.

A company developing rare-disease treatments will webcast a Boston conference chat Nov. 10.

https://www.stocktitan.net/news/LRMR/larimar-therapeutics-to-participate-in-the-guggenheim-3rd-annual-33gaohit28y6.html
Larimar Therapeutics (Nasdaq: LRMR), a clinical-stage biotechnology company, announced its management will participate in the Guggenheim 3rd Annual Healthcare Innovation Conference in Boston from November 9-11, 2026. A fireside chat featuring Larimar management is scheduled for November 10, 2026, at 10:00 AM EST, and the company will also hold 1x1 investor meetings. A replay of the fireside chat will be available for 30 days on Larimar's website.
Advertisement

Larimar Therapeutics to Participate in the Guggenheim 3rd Annual Healthcare Innovation Conference

https://www.globenewswire.com/news-release/2026/11/04/3395824/0/en/larimar-therapeutics-to-participate-in-the-guggenheim-3rd-annual-healthcare-innovation-conference.html
Larimar Therapeutics (Nasdaq: LRMR), a clinical-stage biotechnology company, announced its management team will participate in the Guggenheim 3rd Annual Healthcare Innovation Conference. The team will engage in a fireside chat and one-on-one investor meetings from November 9-11, 2026, in Boston, MA. A webcast of the fireside chat, scheduled for November 10, 2026, at 10:00 AM EST, will be available, with a replay accessible for 30 days on the company's website.

Larimar Therapeutics to Participate in the Guggenheim 3rd Annual Healthcare Innovation Conference

https://finance.yahoo.com/healthcare/articles/larimar-therapeutics-participate-guggenheim-3rd-210500129.html
Larimar Therapeutics, Inc. (Nasdaq: LRMR) announced its participation in the Guggenheim 3rd Annual Healthcare Innovation Conference. Management will host a fireside chat on November 10, 2026, at 10:00 AM EST, and engage in one-on-one investor meetings. The company is a clinical-stage biotechnology firm focused on developing treatments for rare diseases, with its lead compound, nomlabofusp, targeting Friedreich's ataxia.

Larimar Therapeutics(LRMR) Stock Options Chain | Quotes & News

https://www.moomoo.com/stock/LRMR-US/options-chain?chain_id=Name1K9-3FXPhg.1lddbo0&global_content=%7B%22promote_id%22%3A13764,%22sub_promote_id%22%3A39,%22f%22%3A%22www.moomoo.com%2Fus%2Flearn%2Foptions-pricing%22%7D
This page provides detailed options chain data for Larimar Therapeutics (LRMR), including stock quotes, market capitalization, P/E ratio, trading volume, and 52-week high/low. It also lists call and put options with their respective open interest, turnover, volume, and price changes. The article offers a comprehensive overview for investors tracking LRMR's stock and options performance.

Larimar Therapeutics, Inc. Estimates – NASDAQ:LRMR

https://www.tradingview.com/symbols/NASDAQ-LRMR/financials-estimates/
This article provides an overview of financial estimates for Larimar Therapeutics, Inc. (NASDAQ: LRMR) available on TradingView. It highlights sections for exploring reported financial data and analyst estimates across income statements, balance sheets, cash flow statements, and valuation metrics. The platform allows users to compare actual results with average, high, and low estimates and visualize trends over time.

Larimar Therapeutics, Inc. Estimates – GETTEX:ZA71

https://www.tradingview.com/symbols/GETTEX-ZA71/financials-estimates/
This page on TradingView provides financial data and analyst estimates for Larimar Therapeutics, Inc. (GETTEX:ZA71). Users can explore reported financial data and compare actual results with average, high, and low estimates across income statements, balance sheets, cash flow statements, and valuation metrics. The platform also allows visualization of trends over time for both annual and quarterly data.
Advertisement

LRMR - Rolling Biologics Filing And Global Phase III Trial Will Transform This Rare Disease Platform

https://simplywall.st/community/narratives/us/pharmaceuticals-biotech/nasdaq-lrmr/larimar-therapeutics/ants5tk6-rolling-biologics-filing-and-global-phase-iii-trial-will-transform-this-rare-disease-platform
Larimar Therapeutics (LRMR) is poised to transform its rare disease platform through a rolling biologics filing and a global Phase III trial for nomlabofusp, targeting Friedreich's Ataxia. Analysts predict the company is undervalued, expecting significant revenue growth and a positive profit margin by 2029 if nomlabofusp secures accelerated approval. Key risks include regulatory concerns regarding anaphylaxis events and an ongoing legal investigation, which could impact the company's financial trajectory.

Form 4 Larimar Therapeutics Inc: John B. Harlow Jr (President and COO) For: 29 September

https://in.investing.com/news/stock-market-news/form-4-larimar-therapeutics-inc-john-b-harlow-jr-president-and-coo-for-29-september-93CH-5639299
This article reports on a Form 4 filing for Larimar Therapeutics Inc., detailing insider trading activity by John B. Harlow Jr., who holds the positions of President and COO. The filing pertains to transactions that occurred on September 29. The article provides the company's stock symbol (LRMR) and indicates a recent price performance increase of 10.14%.

Form 4 Larimar Therapeutics Inc: John B. Harlow Jr (President and COO) For: 29 September

https://au.investing.com/news/stock-market-news/form-4-larimar-therapeutics-inc-john-b-harlow-jr-president-and-coo-for-29-september-93CH-4697422
This article reports on a Form 4 filing for Larimar Therapeutics Inc, indicating activity by John B. Harlow Jr, who serves as President and COO. The filing is specifically noted for September 29th. The article provides only this essential information without further details on the nature of the transaction.

Form 4 Larimar Therapeutics Inc: John B. Harlow Jr (President and COO) For: 29 September

https://uk.investing.com/news/stock-market-news/form-4-larimar-therapeutics-inc-john-b-harlow-jr-president-and-coo-for-29-september-93CH-4916436
This article reports on a Form 4 filing for Larimar Therapeutics Inc., specifically detailing transactions made by John B. Harlow Jr., who holds the positions of President and COO. The filing date mentioned in the title is September 29th.

Larimar Therapeutics (NasdaqGM:LRMR) Aktienprognose & Analystenprognosen

https://simplywall.st/de/stocks/us/pharmaceuticals-biotech/nasdaq-lrmr/larimar-therapeutics/future
Larimar Therapeutics (NasdaqGM:LRMR) is forecasted to achieve annual earnings and revenue growth of 55.2% and 57.8% respectively, with a projected breakeven date in 2028. The company's lead candidate, nomlabofusp, for Friedreich's ataxia has received Breakthrough Therapy Designation from the FDA and is progressing through a rolling BLA submission, despite ongoing safety concerns related to anaphylaxis. Recent updates include a new President and COO appointment, various price target changes by analysts, and legal probes regarding clinical trial safety disclosures.
Advertisement

Larimar Therapeutics, Inc. Stock 12‑Month Price Target Raised to $14.89, Implies 451% Upside

https://www.tradingview.com/news/tradingview:69f40bc471d7f:0-larimar-therapeutics-inc-stock-12-month-price-target-raised-to-14-89-implies-451-upside/
Larimar Therapeutics, Inc. (LRMR) has seen its average 12-month price target raised to $14.89 from $14.4, based on estimates from 9 analysts, implying a 451% potential upside. The consensus rating remains a "Buy" across 10 covering analysts, with no Holds or Sells. This updated target is based on the October 8th closing price and includes forecasts ranging from $5 to $26 per share.

Larimar Therapeutics Appoints John B. Harlow Jr. as President and COO

https://kalkinemedia.com/us/news/announcements/larimar-therapeutics-appoints-john-b-harlow-jr-as-president-and-coo
Larimar Therapeutics, Inc. has announced the appointment of John B. Harlow Jr. as President and Chief Operating Officer, effective September 29, 2026. An SEC filing confirmed his new roles, noting that he did not beneficially own any company securities at the time of reporting. Harlow will now be subject to ongoing Section 16(a) reporting requirements for future transactions.

John Harlow Joins Larimar Therapeutics as President and Chief Operating Officer

https://biobuzz.io/news/john-harlow-joins-larimar-therapeutics-as-president-and-chief-operating-officer/
Larimar Therapeutics, a clinical-stage biotechnology company, has appointed John Harlow as President and Chief Operating Officer, effective September 29, 2026. Harlow brings over 25 years of commercial, operational, and business development experience in biopharma, and will report to CEO Carole Ben-Maimon. His appointment is key as Larimar advances its lead compound, nomlabofusp, for Friedreich’s ataxia toward potential approval and aims for global launch and long-term growth.

Larimar Therapeutics, Inc. (LRMR) Stock Price, News, Quote & History

https://ca.finance.yahoo.com/quote/LRMR/
This Yahoo Finance page provides a comprehensive overview of Larimar Therapeutics, Inc. (LRMR), a clinical-stage biotechnology company. It includes stock price data, historical performance, key financial metrics, company overview, recent news, earnings trends, and analyst insights. The company focuses on developing treatments for rare diseases, with its lead product candidate, CTI-1601, currently in Phase 2 clinical trials for Friedreich's ataxia.

Larimar Therapeutics names John Harlow president and COO By Investing.com

https://za.investing.com/news/stock-market-news/larimar-therapeutics-names-john-harlow-president-and-coo-93CH-4483138
Larimar Therapeutics, Inc. has announced the appointment of John Harlow as its new President and Chief Operating Officer, effective immediately. Harlow brings over 25 years of experience in the biopharmaceutical industry, having held significant roles at companies like Esperion Therapeutics and Melinta Therapeutics. In connection with his appointment, he received an inducement award of stock options and restricted stock units.
Advertisement
Advertisement
Advertisement
Advertisement

Sign Up free to view live trades and discussion forum to make more informed financial decisions. No credit card is required for sign up!
View Daily Trades
Join Discussion

Advertisement
Advertisement
Advertisement
Advertisement